Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jan-Feb;66 Suppl 1(Suppl 1):S101-4.
doi: 10.1016/j.ihj.2013.12.034. Epub 2013 Dec 31.

Cost-effectiveness of implantable cardioverter-defibrillator in today's world

Giuseppe Boriani  1 , Paolo Cimaglia  2 , Mauro Biffi  2 , Cristian Martignani  2 , Matteo Ziacchi  2 , Cinzia Valzania  2 , Igor Diemberger  2
Affiliations
Review

Cost-effectiveness of implantable cardioverter-defibrillator in today's world

Giuseppe Boriani et al. Indian Heart J. 2014 Jan-Feb.

Abstract

The implantable cardioverter-defibrillator (ICD) is an example of an effective intervention with high up-front costs and delayed benefits. It has become a proven and well-accepted therapy not only for secondary but also for primary prevention of sudden cardiac death in patients with ischemic and non-ischemic heart disease. In recent years, the international guidelines have extended the indications to the prophylactic ICD, increasing the number of eligible patients and, together, the financial challenges of a widespread implementation. In this article, we review the available economic tools that can help address the ICD cost issue. We think that the awareness of such knowledge may facilitate dialogues between physicians, administrators and policy-makers, and help foster rational decision making.

Keywords: Cost-effectiveness; Costs; Heart failure; Implantable cardioverter-defibrillator; Sudden cardiac death.

PubMed Disclaimer

References

    1. Krumholz H.M., Weintraub W.S., Bradford W.D. Task force #2–the cost of prevention: can we afford it? Can we afford not to do it? 33rd Bethesda Conference. J Am Coll Cardiol. 2002;40:603–615. - PubMed
    1. Boriani G., Biffi M., Martignani C. Cardioverter-defibrillators after MADIT-II: the balance between weight of evidence and treatment costs. Eur J Heart Fail. 2003;5:419–425. - PubMed
    1. Stevenson L.W. Implantable cardioverter-defibrillators for primary prevention of sudden death in heart failure: are there enough bangs for the bucks? Circulation. 2006;114:101–103. - PubMed
    1. Priori S.G., Aliot E., Blømstrom-Lundqvist C. Task force on sudden cardiac death, European society of cardiology. Europace. 2002;4:3–18. - PubMed
    1. Nanthakumar K., Epstein A.E., Kay G.N. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. J Am Coll Cardiol. 2004;44:2166–2172. - PubMed

MeSH terms